2 days Ago By ABMN Staff
Russell Investments Group Ltd. lowered its holdings in shares of MoonLake Immunotherapeutics ( NASDAQ:MLTX – Free Report ) by 9.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC).
The firm owned 55,890 shares of the company’s stock after selling 6,140 shares during the quarter. Russell Investments Group Ltd. owned 0.
09% of MoonLake Immunotherapeutics worth $3,026,000 at the end of the most recent quarter. Several other institutional investors have also modified their holdings of MLTX. Alliancebernstein L.
P. raised its holdings in MoonLake Immunotherapeutics by 2.5% during the 4th quarter.
Alliancebernstein L.P. now owns 1,022,604 shares of the company’s stock worth $55,374,000 after buying an additional 24,464 shares during the period.
Rice Hall James & Associates LLC increased its position in shares of MoonLake Immunotherapeutics by 47.3% during the fourth quarter. Rice Hall James & Associates LLC now owns 111,133 shares of the company’s stock worth $6,018,000 after acquiring an additional 35,664 shares in the last quarter.
State Street Corp raised its holdings in shares of MoonLake Immunotherapeutics by 96.2% during the third quarter. State Street Corp now owns 87,637 shares of the company’s stock worth $4,419,000 after acquiring an additional 42,980 shares during the period.
Harbor Capital Advisors Inc. lifted its position in MoonLake Immunotherapeutics by 2.8% in the 4th quarter.
Harbor Capital Advisors Inc. now owns 79,648 shares of the company’s stock valued at $4,313,000 after acquiring an additional 2,180 shares in the last quarter. Finally, Congress Asset Management Co.
lifted its position in MoonLake Immunotherapeutics by 9.5% in the 4th quarter. Congress Asset Management Co.
now owns 72,993 shares of the company’s stock valued at $3,953,000 after acquiring an additional 6,352 shares in the last quarter. Institutional investors own 93.85% of the company’s stock.
Analyst Upgrades and Downgrades MLTX has been the topic of several recent research reports. The Goldman Sachs Group dropped their price target on MoonLake Immunotherapeutics from $82.00 to $73.
00 and set a “buy” rating on the stock in a research note on Thursday, February 27th. Needham & Company LLC lifted their target price on MoonLake Immunotherapeutics from $62.00 to $66.
00 and gave the company a “buy” rating in a research report on Thursday, February 27th. Royal Bank of Canada assumed coverage on MoonLake Immunotherapeutics in a research note on Tuesday, March 18th. They issued an “outperform” rating and a $67.
00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of MoonLake Immunotherapeutics in a research note on Thursday, February 27th.
One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $80.
50. MoonLake Immunotherapeutics Stock Up 0.5 % MLTX stock opened at $36.
97 on Thursday. The company has a market cap of $2.37 billion, a price-to-earnings ratio of -28.
66 and a beta of 1.32. MoonLake Immunotherapeutics has a twelve month low of $31.
42 and a twelve month high of $58.26. The business has a 50 day moving average price of $39.
26 and a two-hundred day moving average price of $46.21. MoonLake Immunotherapeutics ( NASDAQ:MLTX – Get Free Report ) last released its quarterly earnings data on Wednesday, February 26th.
The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.
09). On average, equities research analysts anticipate that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.
MoonLake Immunotherapeutics Company Profile ( Free Report ) MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Further Reading Receive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
_0.jpg?itok=yAIF6nFK)
